Audit: QRS - Oxiracetam for Health & Longevity
Audit conducted on 02/07/2026 06:12 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 91 |
| Failed | 0 |
| N/A | 0 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER (Protocol, Benefits, Risks, Interactions, Monitoring, Conclusion). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Speculative/unproven framing preserved (e.g., “long-term value and safety remain unproven”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “no proven benefit” mirrors ER “no direct evidence”; contraindications kept as avoid-level. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications, interactions, benefits, risks, monitoring all drawn from matching ER sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no citations, PMIDs, NCT IDs, or expert names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, cautious, evidence-graded tone consistent with the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert yet accessible framing maintained. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence without prescribing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No directive medical advice; disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented, not recommended. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain-language phrasing throughout; technical terms glossed where used. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Card content is compact and condensed. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing suits proactive longevity-oriented readers. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring detail assumes an effort-willing audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not aimed at the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Longevity-relevant weighting preserved. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | Uses “longevity” / “brain-aging”; no “anti-aging” voice. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Uses formal terms (e.g., “orally”, “gastrointestinal upset”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: card/section headings, gate headings, tier labels, Monitoring column headers. | 🟢 | All fixed headings and labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | 51 distinct data-qrs-var spans present, matching the template. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Unaddressed spans (e.g., time_3, benefits_high, risks_high) left as template defaults/hidden. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | No empty sections require empty-state phrasing; empty tiers hidden via display:none. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Labels (Standard Dose, Timing, markers) match ER wording. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels faithful to the ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). | 🟢 | No emoji indicators in the QRS body. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to one page; interactions trimmed to three caution-level items. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after doctype (lines 2-14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted. | 🟢 | YAML delimited by — at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. | 🟢 | Values clean; only duration is quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: oxiracetam_2026-0702-0515_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.5.18 (line 5). |
| 5.7 | Creation date and time is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0702-0515 (line 6). |
| 5.8 | The nickname of the AI is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8 (line 8). |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8” is nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: oxiracetam_2026-0702-0515_Opus_QRS.html (line 9). |
| 5.13 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. | 🟢 | Values consistent and trimmed. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Oxiracetam for Health & Longevity - Quick Reference Sheet” (line 22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Oxiracetam for Health & Longevity” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0702-0515 → 07/02/2026 (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8” (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only title, date, and model; no extra content. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 382-384). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 53 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Head-injury signal, weak vascular evidence, no healthy-adult benefit, mild short-term safety all trace to the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain terms (“brain compound”, “cognitive enhancer”, “blood-flow-related”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from “Populations who should avoid it” (ER line 256). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Pregnancy/breastfeeding, children/adolescents, kidney impairment, seizure/anxiety. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> items (lines 541-544). |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Concise; no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “(eGFR below 30 mL/min/1.73m²)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize the items to a plain comma-separated list rather than carrying the bare symbol. | 🟢 | No such ranking notation in the source contraindications. |
| 8.7 | If no [stop_items] are present the section is left empty | 🟢 | Contraindications exist and are populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER interactions bullets (lines 246-250). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications | 🟢 | Three caution-severity interactions carried; monitor-level items and contraindications excluded. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Three <li> items (lines 550-552). |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Concise; trailing rationale stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | Example drug lists preserved for each item. |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list rather than carrying the bare symbol. | 🟢 | No ranking notation in source interactions. |
| 9.7 | If no [caution_items] are present the section is left empty | 🟢 | Interactions exist and are populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol (lines 274-284). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing, and dose-splitting are the key actionable aspects. |
| 10.3 | If less than three distinct actionable aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | Three aspects available; all three sets used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated from the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Two time-to-effect aspects exist in the ER; both surfaced. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Cognitive benefit (weeks-months) precedes acute effect (~1 hour). |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | Third set hidden via display:none (line 503). |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used sets populated from ER Practical Considerations (line 325). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
🟢 | ER provides time-to-effect data; section retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from ER Expected Benefits (lines 144-178). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanisms. | 🟢 | Concise benefit labels only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | No parenthetical detail carried into benefits. |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not empty-state phrasing. | 🟢 | benefits_high hidden via display:none (line 521); no High tier in ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from ER Potential Risks (lines 194-228). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanisms. | 🟢 | Concise risk labels only. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | Medium-tier parenthetical “(insomnia, agitation, headache)” mirrors the ER heading’s own symptom specification, not a stripped category. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not empty-state phrasing. | 🟢 | risks_high hidden via display:none (line 563); no High tier in ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER Monitoring Protocol (lines 345-356). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | eGFR, serum creatinine, blood pressure, baseline cognitive score all listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated (baseline, periodic kidney recheck, cognitive retest at 4-8 weeks then 3-6 months). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER “Qualitative markers” (lines 358-364). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five qualitative markers listed. |
Issues 02/07/2026 06:12
Pass rate 100.00%. No issues found.
Issues 02/07/2026 06:07
- 11.3 — Unused time set not hidden: Only two time-to-effect aspects exist in the ER, but the unused time_3 set retains literal placeholder text
[time_3_label],[time_3_value],[time_3_sub](lines 505, 508, 511) and lacksdisplay:none, so the raw placeholders render on the page instead of being left empty and made invisible.
Fixes 02/07/2026 06:07
- 11.3 — Unused time set now hidden: Emptied the time_3 label/value/sub spans (removed the literal
[time_3_label],[time_3_value],[time_3_sub]placeholders) and addedstyle="display:none"to the time_3 pcell so the unused set is left empty and invisible instead of rendering raw placeholders.